| Name | DnaJ homolog subfamily B member 4 | ||
| UniProt ID | DNJB4_HUMAN | ||
| Gene Name | DNAJB4 | ||
| Gene ID | 11080 | ||
| Synonyms |
DNAJB4, CMYP21, DNAJW, DjB4, HLJ1
|
||
| Sequence |
MGKDYYCILGIEKGASDEDIKKAYRKQALKFHPDKNKSPQAEEKFKEVAEAYEVLSDPKK
REIYDQFGEEGLKGGAGGTDGQGGTFRYTFHGDPHATFAAFFGGSNPFEIFFGRRMGGGR DSEEMEIDGDPFSAFGFSMNGYPRDRNSVGPSRLKQDPPVIHELRVSLEEIYSGCTKRMK ISRKRLNADGRSYRSEDKILTIEIKKGWKEGTKITFPREGDETPNSIPADIVFIIKDKDH PKFKRDGSNIIYTAKISLREALCGCSINVPTLDGRNIPMSVNDIVKPGMRRRIIGYGLPF PKNPDQRGDLLIEFEVSFPDTISSSSKEVLRKHLPAS |
||
| Pathway Map | MAP LINK | ||
| KEGG ID | hsa11080 | ||
| Pfam | PF00226; PF01556 | ||
| Pair Name | Bisdemethoxycucurmin, Icotinib | |||
| Phytochemical | Bisdemethoxycucurmin | |||
| Drug | Icotinib | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Regulate Info | Up-regulation | DnaJ homolog subfamily B member 4 | Expression | |
| Result | Our data indicate that BMDC has the potential to improve the treatment of primary EGFR-TKI resistant NISCLC that cannot be controlled with single-target agent, such as icotinib. | |||
